BACKGROUND:

The Brucellae are facultative intracellular bacteria that cause Brucellosis, one of the major neglected zoonoses. In endemic areas, vaccination is the only effective way to control this disease. Brucella melitensis Rev 1 is a vaccine effective against the brucellosis of sheep and goat caused by B. melitensis, the commonest source of human infection. However, Rev 1 carries a smooth lipopolysaccharide with an O-polysaccharide that elicits antibodies interfering in serodiagnosis, a major problem in eradication campaigns. Because of this, rough Brucella mutants lacking the O-polysaccharide have been proposed as vaccines.

METHODOLOGY/PRINCIPAL FINDINGS:

To examine the possibilities of rough vaccines, we screened B. melitensis for lipopolysaccharide genes and obtained mutants representing all main rough phenotypes with regard to core oligosaccharide and O-polysaccharide synthesis and export. Using the mouse model, mutants were classified into four attenuation patterns according to their multiplication and persistence in spleens at different doses. In macrophages, mutants belonging to three of these attenuation patterns reached the Brucella characteristic intracellular niche and multiplied intracellularly, suggesting that they could be suitable vaccine candidates. Virulence patterns, intracellular behavior and lipopolysaccharide defects roughly correlated with the degree of protection afforded by the mutants upon intraperitoneal vaccination of mice. However, when vaccination was applied by the subcutaneous route, only two mutants matched the protection obtained with Rev 1 albeit at doses one thousand fold higher than this reference vaccine. These mutants, which were blocked in O-polysaccharide export and accumulated internal O-polysaccharides, stimulated weak anti-smooth lipopolysaccharide antibodies.

CONCLUSIONS/SIGNIFICANCE:

The results demonstrate that no rough mutant is equal to Rev 1 in laboratory models and question the notion that rough vaccines are suitable for the control of brucellosis in endemic areas.

Related Articles
Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep.
Vaccine. 2009
Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep.
Barrio MB, Grilló MJ, Muñoz PM, Jacques I, González D, de Miguel MJ, Marín CM, Barberán M, Letesson JJ, Gorvel JP, et al. Vaccine. 2009 Mar 10; 27(11):1741-9. Epub 2009 Jan 30.
Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model.
Infect Immun. 2003
Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model.
Monreal D, Grilló MJ, González D, Marín CM, De Miguel MJ, López-Goñi I, Blasco JM, Cloeckaert A, Moriyón I. Infect Immun. 2003 Jun; 71(6):3261-71.
Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis.
Vaccine. 2004
Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis.
Cloeckaert A, Jacques I, Grilló MJ, Marín CM, Grayon M, Blasco JM, Verger JM. Vaccine. 2004 Jul 29; 22(21-22):2827-35.
Review Rough vaccines in animal brucellosis: structural and genetic basis and present status.
Vet Res. 2004
Review Rough vaccines in animal brucellosis: structural and genetic basis and present status.
Moriyón I, Grilló MJ, Monreal D, González D, Marín C, López-Goñi I, Mainar-Jaime RC, Moreno E, Blasco JM. Vet Res. 2004 Jan-Feb; 35(1):1-38.
Review A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats.
Prev Vet Med. 1997
Review A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats.
Blasco JM. Prev Vet Med. 1997 Aug; 31(3-4):275-83.
The epitopic and structural characterization of Brucella suis biovar 2 O-polysaccharide demonstrates the existence of a new M-negative C-negative smooth Brucella serovar.
PLoS One. 2013
The epitopic and structural characterization of Brucella suis biovar 2 O-polysaccharide demonstrates the existence of a new M-negative C-negative smooth Brucella serovar.
Zaccheus MV, Ali T, Cloeckaert A, Zygmunt MS, Weintraub A, Iriarte M, Moriyón I, Widmalm G. PLoS One. 2013; 8(1):e53941. Epub 2013 Jan 15.
Comparative genomics of early-diverging Brucella strains reveals a novel lipopolysaccharide biosynthesis pathway.
MBio. 2012
Comparative genomics of early-diverging Brucella strains reveals a novel lipopolysaccharide biosynthesis pathway.
Wattam AR, Inzana TJ, Williams KP, Mane SP, Shukla M, Almeida NF, Dickerman AW, Mason S, Moriyón I, O'Callaghan D, et al. MBio. 2012; 3(5):e00246-12. Epub 2012 Aug 28.
Caspase-2-dependent dendritic cell death, maturation, and priming of T cells in response to Brucella abortus infection.
PLoS One. 2012
Caspase-2-dependent dendritic cell death, maturation, and priming of T cells in response to Brucella abortus infection.
Li X, He Y. PLoS One. 2012; 7(8):e43512. Epub 2012 Aug 22.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster